Brightpath Biotherapeutics submitted an Investigational New Drug (IND) application to the FDA to start a Phase I trial of BP-2202 in the United States for multiple myeloma, according to the company. The planned study is registered as NCT07667868. BP-2202’s entry into early clinical testing expands Brightpath’s pipeline into a high-need hematologic oncology space, where new mechanisms and combinations are continuously being pursued to improve response depth and duration. The filing marks a near-term regulatory milestone for BP-2202 and sets up forthcoming updates on dosing, safety, and early pharmacodynamic readouts as the program moves into the clinic.